Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia

Therapeutic Drug Monitoring

Volumn 19, Issue 2, 1997, Pages 219-223

  Chong, Slow Ann ^a,b   Tan, Chay Hoon ^a   Khoo, Yok Moi ^a   Lee, How Sung ^a   Wong, Kim Eng ^a   Ngui, Francis ^a   Winslow, Munidasa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Chinese; Clozapine; Schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; ETHNIC DIFFERENCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; CHINA; CLOZAPINE; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 0031439716     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199704000-00018     Document Type: Article

References (29)

1. Alvir JMJ, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994;55(Suppl B):137-8.
2. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55(Suppl B):107-9.
3. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994;55:9(Suppl B):78-81.
4. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989;99:S38-S40.
5. Ackenheil M. Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 1989;99: S32-S37.
6. Trappler B, Kwong V, Leeman CP. Therapeutic effect of clozapine at an unusually high plasma level. Am J Psychiatry 1996;153:133-4.
7. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-5.
8. Hagegawa M, Gutierrez-Esteinou R, Way L, Meltzer H. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacology 1993;13:383-90.
9. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl B):111-21.
10. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
11. Heimke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Miller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
12. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1983;38:471-3.
13. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
14. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50:508-19.
15. Rudorfer MV. Pharmacokinetics of psychotropics in special populations. J Clin Psychiatry 1993;59(Suppl B):50-4.
16. Lin KM, Poland RE, Nuccio I, Matsuda K, Hathuc N, Su TP, FU P. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989;146:1307-11.
17. Overall JE. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
18. Guy W. Clinical global impression. ECDEU assessment manual for psychopathology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health, 1976.
19. Simpson G, Angus JSW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;(Suppl):9-11.
20. Kane J, Honigfeld G, Singer J, Meltzer H, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
21. Wihhelm D, Kemper A. High-performance liquid chromatographic procedure for the determination of clozapine, haloperidol, droperidol and several benzodiazepines in plasma. J Chromatogr 1990;525:218-24.
22. Lam FYW, Jann MW, Chan WH, Yu HS, Lin SK, Chen H, Davis CM. Intra- and Interethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol 1995;35:128-36.
23. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-5.
24. DeLeon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995;152:453-455.
25. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatient. Am J Psychiatry 1986;146:993-7.
26. Relling MV, Lin JS, Ayers CG, Evans WE. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33:591-602.
27. Cheng YF, Lundberg T, Bondesson U, Lindstrom L, Gabrielsson J. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988;34:445-9.
28. Potkin SG, Bera R, Gulasekaram B, Costa J, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55 (Suppl B):133-6.
29. Kerwin RW, Pilowsky L, Munro J, Shikh S, Gill M, Collier D. Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. J Clin Psychiatry 1994;55(Suppl B):57-62.